Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men

[1]  G. Hovingh,et al.  Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific , 2022, Journal of the American Heart Association.

[2]  J. González-Juanatey,et al.  Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry , 2021, Journal of cardiovascular pharmacology.

[3]  G. Francis,et al.  Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). , 2021, Lancet.

[4]  J. Genest,et al.  Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia , 2021, Journal of the American Heart Association.

[5]  J. López-Miranda,et al.  Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. , 2019, Atherosclerosis.

[6]  C. Cannon,et al.  Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials , 2018, Journal of the American Heart Association.

[7]  A. Swislocki,et al.  Adherence to and Persistence With Statin Therapy in a Veteran Population , 2018, The Annals of pharmacotherapy.

[8]  Emily C. O'Brien,et al.  Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. , 2017, Atherosclerosis.

[9]  R. Giugliano,et al.  Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Journal of the American Heart Association.

[10]  J. Tu,et al.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis , 2017, BMJ Open.

[11]  J. Marrugat,et al.  Familial hypercholesterolemia in a European Mediterranean population-Prevalence and clinical data from 2.5 million primary care patients. , 2017, Journal of clinical lipidology.

[12]  W. März,et al.  Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study. , 2016, Atherosclerosis.

[13]  A. Rodday,et al.  Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) , 2016, Circulation.

[14]  R. Plakogiannis,et al.  Women Versus Men: Is There Equal Benefit and Safety from Statins? , 2016, Current Atherosclerosis Reports.

[15]  E. Amsterdam.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[16]  Harald H H W Schmidt,et al.  Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. , 2015, European heart journal.

[17]  V. Vaccarino,et al.  Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011CLINICAL PERSPECTIVE , 2015 .

[18]  S. Boekholdt,et al.  Adherence to guidelines to prevent cardiovascular diseases: The LifeLines cohort study. , 2015, The Netherlands journal of medicine.

[19]  Dirk De Bacquer,et al.  Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. , 2015, Atherosclerosis.

[20]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[21]  Gianluca Trifirò,et al.  Pattern of Statin Use in Southern Italian Primary Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the Treatment? , 2014, PloS one.

[22]  N. Wong.  Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[23]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[24]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[25]  J. Goudevenos,et al.  Sex differentiation with regard to coronary artery disease. , 2013, Journal of cardiology.

[26]  C. Sibley,et al.  Using imputed pre-treatment cholesterol in a propensity score model to reduce confounding by indication: results from the multi-ethnic study of atherosclerosis , 2013, BMC Medical Research Methodology.

[27]  T. Brennan,et al.  Gender and racial disparities in adherence to statin therapy: a meta-analysis. , 2013, American heart journal.

[28]  F. Irie,et al.  Gender difference of association between LDL cholesterol concentrations and mortality from coronary heart disease amongst Japanese: the Ibaraki Prefectural Health Study , 2009, Journal of internal medicine.

[29]  Emilio Ros,et al.  Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. , 2008, The American journal of cardiology.

[30]  M. F. Domínguez-Berjón,et al.  Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA) , 2008 .

[31]  Serfontein Wj,et al.  Prevalence of familial hypercholesterolemia. , 1986, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[32]  J. J. Valenzuela-Fuenzalida,et al.  A systematic review and metaanalysis , 2023 .

[33]  I. Nolte,et al.  Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants , 2017 .

[34]  Cholesterol Treatment Trialists.  Effi cacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015 .

[35]  Original Research Put Into Perspective for the Practicing Clinician , 2014 .

[36]  Md Pgy Kathryn Beldowski.  2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults , 2014 .

[37]  J. Marrugat,et al.  Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. , 2012, Revista espanola de cardiologia.

[38]  Daniel Prieto-Alhambra,et al.  Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). , 2011, Informatics in primary care.

[39]  D. Mattison,et al.  Sex Differences in Pharmacokinetics and Pharmacodynamics , 2009, Clinical pharmacokinetics.

[40]  C. Jansen,et al.  Severity: A meta-analysis , 2006 .